Drug intelligence / Profile preview

Lianhua Dingchuan

Development stage: Unknown
Lead developer: Yiling Pharmaceutical
Administration: Oral

Overview

Lianhua Dingchuan is a Traditional Chinese Medicine (TCM) tablet developed by Shijiazhuang Yiling Pharmaceutical Co., Ltd. for the treatment of chronic persistent bronchial asthma, specifically targeting the "heat asthma syndrome" (热哮证). The formulation is designed to clear heat, resolve phlegm, and relieve wheezing. It has been evaluated in Phase II clinical trials in China to determine its safety, efficacy, and optimal dosage for improving asthma symptoms and respiratory function in patients with persistent bronchial asthma.

Brand names: Lianhua Dingchuan
Other names: Lianhua Dingchuan Tablet连花定喘片

Beyond the preview

Go deeper on Lianhua Dingchuan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lianhua Dingchuan.

Explore the full profile